Summit Therapeutics Inc. - Common Stock (SMMT)
20.79
+1.60 (8.34%)
Summit Therapeutics is a biotechnology company focused on the discovery and development of novel antibiotic therapies
The company specializes in addressing complex infectious diseases, particularly those caused by antibiotic-resistant bacteria. Summit Therapeutics leverages its proprietary drug development platform to create innovative treatments aimed at improving patient outcomes and combating the growing threat of antibiotic resistance. Through its research and clinical programs, the company seeks to bring forward effective solutions to meet unmet medical needs in the realm of infectious diseases.

Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro 10.28%, ConocoPhillips 9.18%
Via Benzinga · March 16, 2025

Via The Motley Fool · March 13, 2025

Via The Motley Fool · March 10, 2025

Via Benzinga · February 28, 2025

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.
Via Stocktwits · February 24, 2025

The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.
Via Benzinga · February 24, 2025

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via Benzinga · February 21, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec."
Via Benzinga · February 3, 2025

Via The Motley Fool · January 30, 2025

12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts.
Via Benzinga · January 26, 2025

Via The Motley Fool · January 23, 2025

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025.
Via Benzinga · January 10, 2025

Via Benzinga · January 8, 2025

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.
Via Benzinga · January 7, 2025

Via The Motley Fool · January 4, 2025